The total return over the past 12 months is +108.53% vs. +20.58% for the S&P 500. So far it's up +20.54% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +108.53% | +56.97% | +32.11% | (3.10%) | (0.31%) | +0.31% |
| Total Return CAGR | +108.53% | +56.97% | +32.11% | (2.70%) | +0.84% | +1.50% |
| Revenue CAGR | +4.13% | +4.86% | +1.19% | (1.21%) | +0.14% | +4.97% |
| Net Income CAGR | N/A | N/A | +136.89% | (6.80%) | (9.50%) | +13.96% |
| EPS CAGR | N/A | N/A | N/A | +37.51% | (7.11%) | (1.69%) |
| Free Cash Flow CAGR | +51.46% | +4.74% | +14.58% | (10.92%) | (6.43%) | +2.62% |
| Operating Cash Flow CAGR | +36.55% | +3.84% | +33.30% | (9.32%) | (5.62%) | +2.56% |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Teva Pharmaceutical Industries Limited (TEVA)
| Year | Start price | End price | TEVA Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $31.21 | $37.62 | +20.54% | +13.68% | +6.86% |
| 2025 | $22.04 | $31.21 | +41.61% | +17.72% | +23.89% |
| 2024 | $10.44 | $22.04 | +111.11% | +24.89% | +86.22% |
| 2023 | $9.12 | $10.44 | +14.47% | +26.19% | (11.72%) |
| 2022 | $8.01 | $9.12 | +13.86% | (18.17%) | +32.03% |
| 2021 | $9.65 | $8.01 | (16.99%) | +28.74% | (45.73%) |
| 2020 | $9.80 | $9.65 | (1.53%) | +18.37% | (19.90%) |
| 2019 | $15.42 | $9.80 | (36.45%) | +31.22% | (67.67%) |
| 2018 | $18.95 | $15.42 | (18.63%) | (4.56%) | (14.07%) |
| 2017 | $36.25 | $18.95 | (46.01%) | +21.70% | (67.71%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
